TG Therapeutics Investigational Trial Site

Phoenix, Arizona 85032

1 studies enrolling now · 3 studies all time

What they study most

Chronic Lymphocytic Leukemia, Multiple Sclerosis, Relapsing Multiple Sclerosis

Studies at this site

• A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS) — Recruiting now
• Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia — Stopped early
• Phase IIa Study of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis — Completed